Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Publication ,  Journal Article
Saito, Y; Stamp, LK; Caudle, KE; Hershfield, MS; McDonagh, EM; Callaghan, JT; Tassaneeyakul, W; Mushiroda, T; Kamatani, N; Goldspiel, BR ...
Published in: Clin Pharmacol Ther
January 2016

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

January 2016

Volume

99

Issue

1

Start / End Page

36 / 37

Location

United States

Related Subject Headings

  • Pharmacology & Pharmacy
  • Humans
  • HLA-B Antigens
  • Guidelines as Topic
  • Genotype
  • Drug Administration Schedule
  • Biomarkers, Pharmacological
  • Allopurinol
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Saito, Y., Stamp, L. K., Caudle, K. E., Hershfield, M. S., McDonagh, E. M., Callaghan, J. T., … Clinical Pharmacogenetics Implementation Consortium, . (2016). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther, 99(1), 36–37. https://doi.org/10.1002/cpt.161
Saito, Y., L. K. Stamp, K. E. Caudle, M. S. Hershfield, E. M. McDonagh, J. T. Callaghan, W. Tassaneeyakul, et al. “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.Clin Pharmacol Ther 99, no. 1 (January 2016): 36–37. https://doi.org/10.1002/cpt.161.
Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016 Jan;99(1):36–7.
Saito, Y., et al. “Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.Clin Pharmacol Ther, vol. 99, no. 1, Jan. 2016, pp. 36–37. Pubmed, doi:10.1002/cpt.161.
Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE, Lee MTM, Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016 Jan;99(1):36–37.
Journal cover image

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

January 2016

Volume

99

Issue

1

Start / End Page

36 / 37

Location

United States

Related Subject Headings

  • Pharmacology & Pharmacy
  • Humans
  • HLA-B Antigens
  • Guidelines as Topic
  • Genotype
  • Drug Administration Schedule
  • Biomarkers, Pharmacological
  • Allopurinol
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences